Navigation Links
Regulus Demonstrates Initial Progress in microRNA Biomarkers MS Collaboration and Receives Milestone Payment from Biogen Idec
Date:11/20/2013

LA JOLLA, Calif., Nov. 20, 2013 /PRNewswire/ -- Regulus Therapeutics Inc. (NASDAQ: RGLS), a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, today announced that it has demonstrated initial progress in its research collaboration with Biogen Idec, M.A. ("Biogen Idec") to discover microRNAs as biomarkers for multiple sclerosis ("MS") and has received a milestone payment.

Regulus has developed a highly reproducible, proprietary platform for extracting, profiling, and analyzing microRNAs from small volumes of serum. Under its collaboration with Biogen Idec, Regulus applied this platform to profile over 400 serum samples from MS patients and compared these samples against those from healthy volunteers in the largest known MS serum profiling experiment performed to date. The results of this large and successful experiment have provided the foundation for identifying potential biomarker signatures for patients with MS. Based on the initial progress, Regulus and Biogen Idec will now work on the next phase of the research collaboration to validate further the microRNA biomarker signatures in patients with relapse-remitting MS, the most common form of the disease. 

"We are very excited about our early success in this collaboration and are hopeful that our efforts advance Biogen Idec's work in treating MS," said Neil W. Gibson, Ph.D., Chief Scientific Officer of Regulus. "Further, we believe that achievement of this milestone assigns significant value to our proprietary technology and demonstrates the potential of our emerging biomarkers platform to support our microRNA therapeutic pipeline." Regulus believes that microRNA biomarkers may be used to select optimal patient segments in clinical trials, to develop companion diagnostics, and to monitor disease progression or relapse. &
'/>"/>

SOURCE Regulus Therapeutics Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology news :

1. Study demonstrates cells can acquire new functions through transcriptional regulatory network
2. New study demonstrates the role of urban greenery in CO2 exchange
3. WALTHAM® demonstrates commitment to scientific dialogue and exchange at international human animal interaction conference
4. Published clinical trial demonstrates efficacy of Sea-Band® for migraine-related nausea
5. University of Toronto study demonstrates impact of adversity on early life development
6. UT Arlington physics team demonstrates new power generation technique
7. First-in-man study demonstrates the therapeutic effect of RNAi gene silencing in cancer treatment
8. Genetic study of house dust mites demonstrates reversible evolution
9. Rotavirus vaccine developed in India demonstrates strong efficacy
10. Fingerprint Cards (FPC) Demonstrates Fingerprint Biometric Touch Sensor for Microsoft Windows 8.1
11. Marvin Test Solutions Demonstrates Next-Generation Armament Test Solutions at Paris Air Show
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/5/2014)... PROVO, Utah , Dec. 4, 2014  Tute ... has raised $2.3 million in Series A1 funding led ... angel investors also participated in the investment round. ... as the healthcare community adopts next-generation sequencing and seeks ... disease," said Reid Robison , MD MBA, and ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/18/2014)... 17, 2014   News Highlights: ... to develop The Partners Data Lake, an agile ... Data Lake will allow researcher and clinicians to ... and the lives of patients , The ... activities across the Partners system, breaking down physical ...
Breaking Biology News(10 mins):Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 2Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 3Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 4Partners HealthCare and EMC Unite to Solve Health Care's Toughest Challenges Using Big Data 5
... Described as a hotspot of botanical diversity, there are ... Several thousand of them are used by traditional healers ... of problems from the common cold to serious diseases ... are will be the focus of The International Center ...
... owners have a new weapon in their pest management ... kills its host, has proven to be quite effective ... tiny pest-devouring insects are considered to be powerful "biocontrol ... management applications. Jean Pierre Kapongo, Ph.D., an entomologist ...
... when you,ve reached the top of a mountain and you ... to plants and animals, as their habitats slowly shift to ... is you can,t go anywhere. Habitats shrink to the vanishing ... to be played out repeatedly and at an accelerating rate ...
Cached Biology News:Study of African traditional medicine will begin world-first clinical trial 2Study of African traditional medicine will begin world-first clinical trial 3Stanford researchers say climate change will significantly increase impending bird extinctions 2Stanford researchers say climate change will significantly increase impending bird extinctions 3Stanford researchers say climate change will significantly increase impending bird extinctions 4
(Date:12/17/2014)... 2014 Gene synthesis and bioengineering ... entered into a technology access and services agreement ... DNA2.0’s proprietary protein engineering technology, known as “ProteinGPS®” ... are extremely excited that the global leader ADM ... proprietary bioengineering technology has now been validated through ...
(Date:12/17/2014)... -- Vermillion, Inc. (NASDAQ: VRML ), a bio-analytic ... next step in its expanded strategy to rebuild the ... naming of current Chief Operating Officer, Valerie Palmieri ... Chairman of the Board and CEO James LaFrance ... are effective January 1, 2015. "Jim and ...
(Date:12/17/2014)... Md. , Dec. 17, 2014 CASI ... company dedicated to the acquisition, development and commercialization of ... for the global market with a primary commercial focus ... it has been granted a Type C meeting with ... the meeting will be held in February 2015.  During ...
(Date:12/17/2014)... LEXINGTON, Mass. , Dec. 17, 2014   ... a biopharmaceutical company developing therapeutic products for rare disorders, ... Healthcare Conference being held in San Francisco, ... , President and Chief Executive Officer, will present on ... p.m. EST).  The presentation will be webcast live and ...
Breaking Biology Technology:ADM and DNA2.0 Enter Into Protein Engineering Technology Access and Service Agreement 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 2Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 3Vermillion Names Valerie Palmieri CEO; James LaFrance to continue as Chairman of Board 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 2CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 3CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 4CASI Pharmaceuticals Granted Type C Meeting With U.S. FDA For ENMD-2076 In Fibrolamellar Carcinoma 5
... (Nasdaq: NTII ), today announced it will release,its ... September,16, 2008., The Company will also host a ... year-end call are as follows:, -- Date: ... ET, 9:30 a.m. CT, 7:30 a.m. PT -- ...
... Heightened interest in therapeutic efficiency, quality and safety of food ... the biotechnology market. Biopharmaceuticals is poised to experience spiraling growth ... stream of products presently in the pipeline. , ... ...
... Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... Anflu(R), a seasonal influenza vaccine, for 2008-2009 Flu ... only split influenza,vaccine produced without preservatives in China. ... its established sales force to,promote the adult dosage ...
Cached Biology Technology:Neurobiological Technologies Announces Dates for 2008 Fiscal Year End Financial Results Conference Call and Presentation at MCF Investor Summit 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 2Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 3Long-Term Investments Remain Critical to Biotechnology Industry Growth, According to a New Report by Global Industry Analysts 4Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season 2Sinovac Launches Seasonal Influenza Vaccine Anflu(R) for 2008-2009 Flu Season 3
Request Info...
Invitrogen's Calcium Phosphate Transfection Kit provides high-quality reagents to enable the introduction of DNA into tissue culture cells via calcium phosphate co-precipitation....
Request Info...
...
Biology Products: